Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This session of the ISGIO 2025 meeting focused on the rapidly changing treatment landscape for esophagogastric cancer, including the evolving use of immunotherapy for resectable disease, and the expanding landscape of targeted and immunological therapies for metastatic disease. These presentations were supplemented by a case discussion on optimizing the use of neoadjuvant therapy for a patient with resectable disease
Registration is
also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft
Lauderdale, Florida. Click here to learn more.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate novel data to effectively sequence available therapies for optimal outcomes in patients with GI cancers
- Apply best practices and evidence-based proactive strategies to monitor and manage treatment-related adverse events in patients receiving novel therapies and combination regimens
- Evaluate the latest efficacy and safety data for newly approved agents, novel combinations, and novel agents to consider their potential impact on evolving treatment paradigms in GI cancers
Joanna Mycek, MD
Y2 Fellow Medical Oncology Program
University of Calgary
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta
Disclosures: Joanna Mycek, MD, has no relevant financial relationships with ineligible companies.
M. Bassam Sonbol, MD
Associate Professor of Medicine
Associate Program Director, Medical Oncology Fellowship
Mayo Clinic
Phoenix, AZ
Disclosures: Consulting Fees (to Institution): Bayer, Boehringer Ingelheim; Consulting Fees (to self): Novartis; Grant/Research Funding (to institution): Eli Lilly, Taiho
Matthew R. Strickland, MD
Director of Translational Research
Center for Space Medicine Research
Massachusetts General Hospital and Harvard Medical School
Boston, MA
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: Astellas Pharma, Bayer, Bristol Myers Squibb, Encapsulate, Sedgwick Claims Management, SOFIE
Vivian E. Strong, MD, FACS
Iris Cantor Endowed Chair of Surgical Oncology
Attending Surgeon
Memorial Sloan Kettering Cancer Center
Professor of Surgery
Weill Cornell Medical College
New York, NY
Disclosures: Speaker’s Bureau: AstraZeneca, Merck
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here